» Download Public Reports
About 100 reports
- Company report
- July 2012
- 7 pages
June 2012
... Commissions, we believe that its earnings will rebound y-y in 2013. On dec 14 of last year, phase ii clinical trials for the company S next generation meditoxin were completed in australia. In terms ...
June 2012
... Up 69.9% Y-y), and net profit of w28.9Bn (up 68.9% Y-y). On dec 14, phase ii clinical trials for the company S next generation meditoxin were completed in australia. We believe that this improved ...
September 2012
... Mean that the company either need to repeat the trial (capital intensive) or write off the drug cand completely. Regulatory risks Upon completion of pre-clinical or clinical studies ...
November 2012
... Irinotecan S activity on cancer stem cells. As this is an investigator-sponsored trial, our involvement in the trial has been limited. We currently do not intend to pursue further clinical trials or commercialization ...
December 2012
... Transferred $25m to fund the final phase of development of diabecell through to market approval. Diabecell is in phase iib clinical trials in argentina and is indicated for the treatment of people ...
January 2013
... Is entirely flawed since it is based on the trional patent and regulatory approval processes while the time lines for drug development are defined by pre-clinical and clinical development times. Quite ...
November 2012
... Portfolio of drug cands during the 2012 financial year, we have considerably advanced our position as a successful, fully integrated, international drug discovery and development company through ...
January 2013
... A common bond was a tacitly agreed permissiveness - carte blanche for whatever your vision to future progress might be. Crisis in drug discovery Opportunities: Aging population in west More ...
August 2012
... On the australian securities exchange (asx:ivx) corporate snapshot sector biotechnology principal activities clinical-stage pharmaceutical drug development intellectual property assets 2 drug cands pipeline ...
» Purchase Premium Reports
(From $ 125 - $ 250)
30 reports
April 2013
$ 250
Summary Australian Centre for Vaccine Development (ACVD) is a vaccine research centre, based in Australia. The centre provides training, develop novel technology platforms to enhance the efficiency of ...
March 2013
$ 250
Summary NeuroDiscovery Ltd (NeuroDiscovery) is a neuroscience drug development company, based in Australia. The company provides neuroscience services and drug development. Its products include NSL-101 ...
April 2013
$ 125
Summary Lupin Limited (Lupin) is transnational pharmaceutical company. The company focuses on the manufacture of generic and branded drugs, formulations and active pharmaceutical ingredients (API's). The ...
